The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to sacituzumab govitecan-hziy (Trodelvy®) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy, according to an announcement from Gilead Sciences, Inc. The Breakthrough Therapy Designation is based on results from the ES-SCLC cohort in the global phase 2 TROPiCS-03 study, “which showed encouraging results with Trodelvy® as a second-line treatment for ES-SCLC,” Gilead officials said in the announcement. ...
Lung Cancers Today
A new medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and more.
Advertisement
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.
This follows the FDA’s August 2024 move to grant Priority Review for the subcutaneous amivantamab BLA.
The phase 2 expansion portion of the trial will enroll approximately 50 patients at 10 to 15 sites in the United States.
Researchers say the conventional criteria may underestimate the condition in Asian patients with lung cancer.
A qualitative study of patients with NSCLC is providing insights into their experiences and perceptions.
Certain groups continue to experience higher rates of lung cancer mortality related to chronic lower respiratory diseases.
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Veterans with high socioeconomic deprivation experience suboptimal access to pre- and postoperative care for NSCLC.
The burden of disease is expected to increase to 4.62 million new cases and 3.55 million deaths by 2050.
Patients with NSCLC, treated with an immunotherapy regimen, have a higher risk of pneumonitis with decreased lung volume.
Advertisement
Roundtable Discussions on Lung Cancer
Expert Interviews on Lung Cancer
Conference Coverage
Find the latest news and updates on lung cancer from the ESMO Congress 2024.
Find the latest updates on lung cancer treatment and research from the IASLC 2024 World Conference on Lung Cancer.
Find the latest updates on lung cancer treatment and research from the 2024 ASCO Annual Meeting.
Our editors detail the latest data and innovations in the lung cancer space presented at ATS 2024.
Our editors deliver in-depth coverage of NACLC 2023, a premier event offering the latest data on lung cancer advancements.
Our editors provide comprehensive coverage of ESMO Congress 2023, with a focus on lung cancer.
Our editors detail the latest data and innovations in the lung cancer space, as presented at WCLC 2023.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.